Zobrazeno 1 - 10
of 71
pro vyhledávání: '"33"'
Autor:
Celestia Davis, Daniel Hughes, Yu Zhang, Diego Altomare, Sapana N. Shah, James C. Ryan, Maria Marjorette O. Peña
Publikováno v:
Cancer Research. 76:C21-C21
The major cause of death from colorectal cancer (CRC) is liver metastasis and understanding its mechanisms is necessary for early diagnosis and development of new therapies. Interleukin-33 (IL-33) is an IL-1 cytokine that functions as a cytokine and
Autor:
Cristina Saura, Mafalda Oliveira, Valentina Gambardella, Kevin Kalinsky, Andrés Cervantes, Naoki Kotani, Ian E. Krop, Zachary William Neil Veitch, Komal Jhaveri, Dejan Juric, Erika Hamilton, Antoine Italiano, Anjali Vaze, Stephanie Royer-Joo, Katie Hutchinson, Peter Schmid, Philippe L. Bedard, Jennifer L. Schutzman, Nicholas C. Turner, Andrea Varga, Amy V. Kapp, Leslie J. Dickmann
Publikováno v:
Cancer Research. 80:P1-19
Background: Dysregulation of the PI3K/AKT/mTOR signaling pathway occurs in solid tumor malignancies. GDC-0077 (G) is a potent p110α-selective, p110α-mutant degrading inhibitor with anti-tumor activity in PIK3CA-mutant breast cancer xenograft models
Autor:
Rosalind P. Candelaria, Beatriz E. Adrada, Mediget Teshome, Elsa Arribas, M Chavez Mac-Gregor, Benjamin Smith, Wei Tse Yang, Gaiane M. Rauch, Sarah M. DeSnyder, Michael Z. Gilcrease, V. Valero, Savitri Krishnamurthy, Anthony Lucci, Brian P. Hobbs, Lumarie Santiago, Henry Mark Kuerer, Abigail S. Caudle, Makesha V. Miggins, Tanya W. Moseley, Rosa F. Hwang, K. K. Hunt
Publikováno v:
Cancer Research. 77:P5-16
Background: Contemporary improved neoadjuvant systemic therapy (NST) for breast cancer may result in a pathologic complete response (pCR) in up to 60% of patients (pts) yet imaging alone has a poor negative predictive value to determine which pts mig
Autor:
William Jeffery Edenfield, Sara M. Tolaney, Maura N. Dickler, Elizabeth Claire Dees, H. A. Burris, Donald A. Richards, T Beck, Teresa Helsten, Muralidhar Beeram, PK Turner, Paul Conkling, Matthew P. Goetz, Edward M. Chan, Shubham Pant, Brent N. Rexer, Kevin Kalinsky, Carlos Becerra, Alison Conlin, Shannon Puhalla, N Cai
Publikováno v:
Cancer Research. 76:P4-13
Background: Abemaciclib, a small molecule inhibitor of CDK4 and CDK6, induces G1 cell cycle arrest in Rb-proficient human cancers.1 The clinical safety profile of abemaciclib enables continuous oral dosing to achieve sustained target inhibition, resu
Autor:
Gilberto de Castro, J. Kobie, Kazuo Kasahara, Bilal Piperdi, Andrey Loboda, Byoung Chul Cho, Tony Mok, M. Catherine Pietanza, Jared Lunceford, Gilberto Lopes, Yi-Long Wu, Mark Ayers, Deepti Aurora-Garg, Dariusz M. Kowalski, Hande Turna, Razvan Cristescu
Publikováno v:
Cancer Research. 80:CT084-CT084
Background: STK11 (also known as LKB1) and KEAP1 mutations have been associated with chemoresistance and poor outcomes and shown to be more frequent in PD-L1-negative tumors with high tumor mutational burden (TMB). We performed an exploratory analysi
Autor:
Rebecca R. Hozak, Carla Visseren-Grul, Sanjay Popat, Santiago Ponce Aix, Makoto Nishio, Kazuto Nishio, Sameera R. Wijayawardana, Kazuhiko Nakagawa, Edward B. Garon, John V. Heymach, Luis Paz-Ares, Martin Reck, Silvia Novello
Publikováno v:
Cancer Research. 80:CT215-CT215
RELAY (NCT02411448) showed a superior progression free survival benefit with RAM+ERL versus (v) PBO+ ERL (mPFS 19.4 vs 12.4mo, HR 0.59, p-value TablePts (≥2 in either treatment group) with treatment emergent alterationsaPop1bPop2bGene NameRAM+ERL (
Autor:
Annette Fontaine, Melissa Plets, Jourdain Hayward, W. Michael Korn, Sandip Pravin Patel, Christopher W. Ryan, Razelle Kurzrock, Elad Sharon, Tareq Al Baghdadi, Marc Matrana, Helen X. Chen, Manisha H. Shah, Charles D. Blanke, Christine MMcLeod, Edward Mayerson, Zoran Gatalica, Preet Paul Singh, Donna E. Hansel, Young Kwang Chae, Megan Othus, Anup Kasi, Francis J. Giles
Publikováno v:
Cancer Research. 79:CT039-CT039
Background: Immune checkpoint blockade, in particular anti-CTLA-4 and anti-PD-1-directed approaches, have improved outcomes in various tumor types. However, little is known about the efficacy of these agents in metastatic rare solid tumors. We report
Autor:
Andrea Sartore-Bianchi, Erika Martinelli, Livio Trusolino, Sara Lonardi, Silvio Veronese, Silvia Marsoni, Daniele Regge, Emanuele Valtorta, Laura Palmeri, Silvia Ghezzi, Patrizia Racca, Cosimo Martino, Salvatore Siena, Fortunato Ciardiello, Alessio Amatu, Francesco Leone, Angelo Vanzulli, Katia Bencardino, Vittorina Zagonel, Alberto Bardelli
Publikováno v:
Cancer Research. 77:CT005-CT005
Background: HER2 amplification is found in 5% of RAS wild type (RASWT) metastatic colorectal cancer (mCRC). Dual HER2 blockade with trastuzumab (T) and lapatinib (L), but not treatment with either drug alone, led to remarkable inhibition of tumor gro
Autor:
Robert O. Dillman, Thomas Amatruda, Carol DePriest, Denysha Carbonell, Andrew N. Cornforth, Edward F. McClay
Publikováno v:
Cancer Research. 76:CT105-CT105
Eltrapuldencel-T (CLBS20) consists of autologous dendritic cells loaded with antigens from irradiated, self-renewing, autologous tumor cells that potentially present the entire repertoire of unique patient-specific tumor-associated antigens resulting
Publikováno v:
Cancer Research. 80:P2-19
Purpose: Diagnosis of bone metastasis (BM) in breast cancer relies on structural changes of bone. We investigated whether circulating osteocalcin-positivecells (cOC) could detect the incipient and/or progressive BM earlier than image-based diagnostic